News Tag: Other Corporate Information

Lipidors noteringsemission tecknades till 540 %

I fredags den 13 september 2019 avslutades teckningstiden i Lipidor AB:s (”Bolaget”) noteringsemission av units inför notering på Nasdaq First North Growth Market. Emissionen om cirka 25,2 MSEK tecknades till totalt 136 MSEK vilket motsvarar en teckningsgrad om cirka 540 %. Bolaget tillförs genom emissionen cirka 1 150 nya aktieägare. Lipidors VD Ola Holmlund kommenterar […]

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing on the Nasdaq First North Growth Market. The issue of approximately SEK 25.2 million was subscribed at SEK 136 million, corresponding to a subscription rate of circa 540%. Through the share issue, the […]

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019. Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the company’s […]

Sista patienten inkluderad i Lipidors fas III-studie med Kalcipotriol/AKVANO spray (AKP01) mot psoriasis

Lipidor AB (publ) meddelar idag att den sista patienten inkluderats i den pågående fas III-studien med bolagets kalcipotriolspray mot mild till måttlig psoriasis. Resultat från studien beräknas presenteras i december 2019. Lipidor har utvecklat en spraybar kalcipotriolprodukt, Kalcipotriol/AKVANO 50 µg/g kutan lösning (AKP01) formulerad i bolagets lipidbaserade AKVANO-teknologi, som ger patienter mer precis dosering och […]

Lipidor AB successfully completes private placement of 20 MSEK

14 January 2019, Stockholm, Sweden. Lipidor AB, a Swedish drug development company with an ongoing fully financed Phase III study for a psoriasis medication, has successfully completed a private placement of 20 MSEK from Swedish and international investors. “We have received very positive feedback from both current and new investors on our outlooks as well […]

Lipidor gets go-ahead for Phase III Clinical Study of new Calcipotriol Spray treatment for psoriasis

India’s CDSCO (Central Drugs Standard Control Organization) has approved Phase III Trials of a new topical anti-psoriatic spray developed by Swedish company Lipidor. The new spray is expected to overcome patient non-compliance, a major problem for traditional psoriasis creams and ointments.   It is exceptionally fast-drying and easy to apply. Calcipotriol Spray consists of the generic […]